Table 2.
Summary of initial treatment delivered among 284 patients
|
EGFR mutation |
Mt – (n= 163) |
Mt + (n= 121) |
||||||
|---|---|---|---|---|---|---|---|---|
| |
IIIB |
IV |
IIIB |
IV |
||||
| |
(n= 19) |
(n= 144) |
(n= 6) |
(n= 115) |
||||
| No. | % | No. | % | No. | % | No. | % | |
| Treatment |
|
|
|
|
|
|
|
|
| Platinum doublet |
4 |
3 |
114 |
70 |
2 |
2 |
54 |
45 |
| Monotherapy |
0 |
|
30 |
18 |
0 |
|
11 |
9 |
| EGFR-TKI |
0 |
|
0 |
|
0 |
|
50 |
41 |
| Chemoradiotherapy |
15 |
9 |
0 |
|
4 |
3 |
0 |
|
| Specific regimens |
|
|
|
|
|
|
|
|
| Cisplatin-pemetrexed |
1 |
|
24 |
15 |
1 |
|
9 |
7 |
| Carboplatin-paclitaxel |
3 |
|
52 |
32 |
0 |
|
27 |
22 |
| Carboplatin-paclitaxel+ bev |
0 |
|
2 |
|
0 |
|
2 |
|
| Other platinum doublets |
0 |
|
36 |
22 |
1 |
|
12 |
10 |
| Gefitinib |
0 |
|
0 |
|
0 |
|
41 |
34 |
| Erlotinib |
0 |
|
0 |
|
0 |
|
7 |
6 |
| Docetaxel |
0 |
|
16 |
10 |
0 |
|
3 |
|
| Vinorelbine |
0 |
|
5 |
|
0 |
|
2 |
|
| Others | 0 | 24 | 15 | 0 | 6 | |||
Mt+: mutant EGFR, Mt-: wild-type EGFR, bev: bevacizumab.